Regeneron Casimvy Gene Therapy from Germany
Casimvy uses CRISPR/Cas9 ex vivo to edit CD34+ cells for sickle cell disease, administered as immunological cell therapy. As a measured-dose biotech product for retail, it fits HTS 3002.15.00.
Duty Rate — Germany → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Patient-specific autologous cells; donor matching documentation
• Cryopreserved transport (-196°C); liquid nitrogen shipper validation
• Distinguish from 3002.90 cell cultures if not therapeutically modified